Integra LifeSciences Holdings Co. (NASDAQ:IART) to Post FY2024 Earnings of $3.17 Per Share, Zacks Research Forecasts

Integra LifeSciences Holdings Co. (NASDAQ:IART) – Research analysts at Zacks Research upped their FY2024 earnings per share (EPS) estimates for Integra LifeSciences in a research note issued to investors on Wednesday, April 3rd. Zacks Research analyst R. Department now expects that the life sciences company will earn $3.17 per share for the year, up from their prior forecast of $3.16. The consensus estimate for Integra LifeSciences’ current full-year earnings is $3.19 per share.

Several other equities research analysts have also issued reports on the company. Truist Financial lowered their price objective on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. StockNews.com downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target on the stock in a report on Wednesday, April 3rd. Finally, JMP Securities reduced their price target on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $44.89.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock opened at $34.61 on Monday. The firm has a market cap of $2.72 billion, a PE ratio of 41.70, a PEG ratio of 1.02 and a beta of 1.12. Integra LifeSciences has a 12 month low of $33.24 and a 12 month high of $59.33. The stock has a 50 day moving average of $38.27 and a 200 day moving average of $39.43. The company has a current ratio of 3.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The business had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. During the same period last year, the company earned $0.94 EPS. The business’s revenue was down .3% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Signaturefd LLC boosted its position in shares of Integra LifeSciences by 248.5% in the 4th quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock worth $25,000 after purchasing an additional 415 shares in the last quarter. Hexagon Capital Partners LLC lifted its position in Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock worth $29,000 after acquiring an additional 370 shares during the period. Itau Unibanco Holding S.A. lifted its position in Integra LifeSciences by 469.5% during the 2nd quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock worth $31,000 after acquiring an additional 615 shares during the period. Gladius Capital Management LP acquired a new stake in Integra LifeSciences during the 3rd quarter worth about $47,000. Finally, Covestor Ltd lifted its position in Integra LifeSciences by 82.5% during the 3rd quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock worth $78,000 after acquiring an additional 921 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.